Thursday, January 22, 2026

PulseSight Completes Enrollment in Gene Therapy Trial

The French company’s PST-611, which is being evaluated in a phase 1 trial, targets iron dysregulation in dry AMD and geographic atrophy.

Tuesday, January 20, 2026

MCO-010 Receives Accelerated Pathway in Japan

Sakigake designation supports expedited review; FDA, EMA, and Japan conditionally approve the brand name Mogenry for Nanoscope’s optogenetic therapy.

Tuesday, January 20, 2026

OCU410 Shows Early Efficacy in GA Trial

Interim ArMaDa data show a reduction in lesion growth with no serious safety signals reported for Ocugen's investigational gene therapy.

Friday, January 16, 2026

AAVantgarde Completes Enrollment in LUCE-1

The phase 1/2 trial is evaluating a dual-AAV gene therapy for Usher syndrome type 1B.

Tuesday, January 13, 2026

Topcon Partners With RemoniHealth on Remote Monitoring

The companies will collaborate on home monitoring and connected care for chronic retinal disease.

Thursday, January 8, 2026

Ollin Biosciences Reports Positive OLN324 Results

The next-generation VEGF/Ang2 bispecific antibody demonstrates rapid retinal drying and vision gains in patients with diabetic macular edema.

Thursday, January 8, 2026

Gene Therapy for GA Receives FDA Fast-Track Designation

Complement Therapeutics’s CTx001, an investigational gene therapy that targets complement pathways in geographic atrophy, will be evaluated in a phase 1/2 trial in 2026.

Wednesday, January 7, 2026

Nanoscope Receives Patent for Optogenetic Platform

The patent extends US intellectual property protection for Nanoscope’s multicharacteristic opsin (MCO) platform through at least 2039.

Tuesday, January 6, 2026

Ikarovec Secures Capsid Option for AMD Program

The partnership with VectorBuilder aims to advance IKAR-003, an intravitreal gene therapy designed to slow AMD progression.

Tuesday, January 6, 2026

Privosegtor Receives Breakthrough Drug Designation

In a phase 2 trial, the drug showed functional and structural signals in optic neuritis.

Friday, January 2, 2026

FDA Approves Ranibizumab Biosimilar

Ranibizumab-leyk (Nufymco) is approved for for wet AMD, DME, DR, RVO-related macular edema, and myopic CNV.

Friday, January 2, 2026

FDA Seeks Additional Efficacy Evidence for ONS-5010

The agency says Outlook Therapeutics must provide additional evidence confirming the efficacy of its intravitreal bevacizumab formulation for wet AMD.

Friday, January 2, 2026

Visual Evoked Potentials Studied to Measure Outcomes in Children Treated With Gene Therapy for RPE65 IRD

Results underscore the potential of alternate objective measures in the pediatric population.